DAWN – Day One Biopharmaceuticals, Inc.
Float Short %
14.74
Margin Of Safety %
Put/Call OI Ratio
0.38
EPS Next Q Diff
0.01
EPS Last/This Y
0.05
EPS This/Next Y
0.43
Price
11.95
Target Price
23.56
Analyst Recom
1.2
Performance Q
64.6
Relative Volume
1.09
Beta
-1.27
Ticker: DAWN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | DAWN | 9.45 | 0.21 | 6.59 | 51101 |
| 2025-12-29 | DAWN | 9.38 | 0.22 | 0.95 | 51546 |
| 2025-12-30 | DAWN | 9.18 | 0.22 | 2.07 | 51583 |
| 2025-12-31 | DAWN | 9.32 | 0.22 | 0.23 | 51608 |
| 2026-01-02 | DAWN | 8.85 | 0.22 | 3.49 | 51837 |
| 2026-01-05 | DAWN | 8.54 | 0.23 | 0.51 | 52813 |
| 2026-01-06 | DAWN | 8.63 | 0.24 | 0.49 | 53793 |
| 2026-01-07 | DAWN | 9.62 | 0.25 | 0.04 | 55056 |
| 2026-01-08 | DAWN | 9.25 | 0.24 | 0.47 | 57726 |
| 2026-01-09 | DAWN | 8.94 | 0.24 | 1.19 | 58264 |
| 2026-01-12 | DAWN | 11.32 | 0.25 | 0.70 | 58720 |
| 2026-01-13 | DAWN | 10.59 | 0.35 | 0.34 | 61812 |
| 2026-01-14 | DAWN | 10.72 | 0.40 | 0.48 | 62986 |
| 2026-01-15 | DAWN | 10.49 | 0.41 | 0.01 | 63357 |
| 2026-01-16 | DAWN | 10.13 | 0.47 | 0.13 | 57937 |
| 2026-01-20 | DAWN | 12.12 | 0.96 | 0.08 | 19688 |
| 2026-01-21 | DAWN | 12.06 | 0.33 | 0.75 | 47098 |
| 2026-01-22 | DAWN | 12.32 | 0.37 | 0.04 | 52598 |
| 2026-01-23 | DAWN | 11.95 | 0.38 | 0.17 | 51905 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | DAWN | 9.44 | 68.1 | - | -0.97 |
| 2025-12-29 | DAWN | 9.38 | 68.1 | - | -0.97 |
| 2025-12-30 | DAWN | 9.18 | 68.1 | - | -0.97 |
| 2025-12-31 | DAWN | 9.32 | 68.1 | - | -0.97 |
| 2026-01-02 | DAWN | 8.85 | 68.1 | - | -0.97 |
| 2026-01-05 | DAWN | 8.54 | 68.1 | - | -0.97 |
| 2026-01-06 | DAWN | 8.63 | 68.1 | - | -0.97 |
| 2026-01-07 | DAWN | 9.61 | 68.1 | - | -0.97 |
| 2026-01-08 | DAWN | 9.25 | 68.1 | - | -0.97 |
| 2026-01-09 | DAWN | 8.93 | 65.7 | - | -0.97 |
| 2026-01-12 | DAWN | 11.32 | 65.7 | - | -0.97 |
| 2026-01-13 | DAWN | 10.59 | 65.7 | - | -0.97 |
| 2026-01-14 | DAWN | 10.73 | 65.7 | - | -0.97 |
| 2026-01-15 | DAWN | 10.50 | 65.7 | - | -0.97 |
| 2026-01-16 | DAWN | 10.14 | 72.6 | - | -0.97 |
| 2026-01-20 | DAWN | 12.11 | 72.6 | - | -0.97 |
| 2026-01-21 | DAWN | 12.06 | 72.6 | - | -0.97 |
| 2026-01-22 | DAWN | 12.33 | 72.6 | - | -0.97 |
| 2026-01-23 | DAWN | 11.95 | 72.6 | - | -0.97 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | DAWN | -0.19 | -0.89 | 12.73 |
| 2025-12-29 | DAWN | -0.19 | -0.89 | 12.73 |
| 2025-12-30 | DAWN | -0.19 | -0.89 | 12.73 |
| 2025-12-31 | DAWN | -0.19 | -0.89 | 12.73 |
| 2026-01-02 | DAWN | -0.19 | -0.89 | 12.73 |
| 2026-01-05 | DAWN | -0.19 | -0.88 | 12.73 |
| 2026-01-06 | DAWN | -0.19 | -0.88 | 12.73 |
| 2026-01-07 | DAWN | -0.19 | -0.88 | 12.73 |
| 2026-01-08 | DAWN | -0.19 | -0.88 | 12.73 |
| 2026-01-09 | DAWN | -0.19 | -0.88 | 12.73 |
| 2026-01-12 | DAWN | -0.18 | -0.88 | 12.36 |
| 2026-01-13 | DAWN | -0.19 | -0.88 | 14.74 |
| 2026-01-14 | DAWN | -0.19 | -0.88 | 14.74 |
| 2026-01-15 | DAWN | -0.19 | -0.88 | 14.74 |
| 2026-01-16 | DAWN | -0.19 | -0.88 | 14.74 |
| 2026-01-20 | DAWN | -0.19 | -0.01 | 14.74 |
| 2026-01-21 | DAWN | -0.19 | -0.01 | 14.74 |
| 2026-01-22 | DAWN | -0.19 | -0.01 | 14.74 |
| 2026-01-23 | DAWN | -0.19 | -0.01 | 14.74 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.19
Avg. EPS Est. Current Quarter
-0.2
Avg. EPS Est. Next Quarter
-0.18
Insider Transactions
-0.19
Institutional Transactions
-0.01
Beta
-1.27
Average Sales Estimate Current Quarter
44
Average Sales Estimate Next Quarter
50
Fair Value
Quality Score
38
Growth Score
26
Sentiment Score
65
Actual DrawDown %
58.4
Max Drawdown 5-Year %
Target Price
23.56
P/E
Forward P/E
PEG
P/S
9.45
P/B
2.72
P/Free Cash Flow
EPS
-1.49
Average EPS Est. Cur. Y
-0.97
EPS Next Y. (Est.)
-0.54
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-113.53
Relative Volume
1.09
Return on Equity vs Sector %
-60.9
Return on Equity vs Industry %
-44.9
EPS 1 7Days Diff
EPS 1 30Days Diff
0.21
EBIT Estimation
Day One Biopharmaceuticals, IncSector: Healthcare
Industry: Biotechnology
Employees: 184
Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I clinical trial for adult and pediatric cancers; and VRK1 Inhibitor which is in pre-clinical stage for adult and pediatric cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
stock quote shares DAWN – Day One Biopharmaceuticals, Inc. Stock Price stock today
news today DAWN – Day One Biopharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch DAWN – Day One Biopharmaceuticals, Inc. yahoo finance google finance
stock history DAWN – Day One Biopharmaceuticals, Inc. invest stock market
stock prices DAWN premarket after hours
ticker DAWN fair value insiders trading